CCM
DMAAU

Context Capital Management’s Drugs Made In America Acquisition Corp Units DMAAU Stock Holding History

Context Capital Management’s Portfolio DMAAU Stock Details DMAAU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-250,000
Closed -$2.58M – 278
2025
Q2 		$2.58M Hold
250,000
– – 0.09% 128
2025
Q1 		$2.54M Buy
+250,000
New +$2.52M 0.1% 112

Other funds holding DMAAU

KC
Kryger Capital London, United Kingdom $1.75B AUM 102.57% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
RCM
Robinson Capital Management Grosse Pointe Farms, Michigan $226M AUM 6.92% 1-Year Est. Return
TCM
Tuttle Capital Management Riverside, Connecticut $148M AUM 64.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Context Capital Management's DMAAU Position: Q3 2025 in Review

Context Capital Management sold out of Drugs Made In America Acquisition Corp Units (DMAAU) in Q3 2025, closing a stake of 250,000 shares — an estimated $2.58M sold.

Context Capital Management first reported a position in DMAAU in Q1 2025 and held it in 2 quarters. The position peaked at $2.58M in Q2 2025. 8 funds tracked by Wall St. Rank hold DMAAU as of Q3 2025.

  • Context Capital Management reported no remaining Drugs Made In America Acquisition Corp Units position as of Q3 2025 after selling out during the quarter.
  • Context Capital Management sold 250,000 Drugs Made In America Acquisition Corp Units shares in Q3 2025, an estimated $2.58M.
  • Context Capital Management first reported a position in Drugs Made In America Acquisition Corp Units in Q1 2025 and held it in 2 quarters.
  • Context Capital Management's Drugs Made In America Acquisition Corp Units position peaked at $2.58M in Q2 2025.
  • 8 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Units as of Q3 2025.

Based on Context Capital Management's 13F filing for Q3 2025, filed 12 Nov 2025.